当前位置: 首页 > 期刊 > 《中国中医药信息杂志》 > 2019年第7期
编号:13367695
黄菟益肾颗粒治疗特发性膜性肾病临床疗效及对尿足细胞糖萼蛋白的影响(4)
http://www.100md.com 2019年7月1日 《中国中医药信息杂志》 2019年第7期
     [16] DROSSOPOULOU G I, TSOTAKOS N E, TSILIBARY E C. Impaired transcription factor interplay in addition to advanced glycation end products suppress podocalyxin expression in high glucose- treated human podocytes[J]. Am J Physiol Renal Physiol,2009, 297(3):F594-603.

    [17] PETERMANN A, FLOEGE J. Podocyte damage resulting in podocyturia:a potential diagnostic marker to assess glomerular disease activity[J]. Nephron Clin Pract,2007,106(2):c61-66.

    [18] HARA M, YANAGIHERE T, KIHARA I, et al. Apical cell membranes are shed into urine from injured podocytes:a novel phenomenon of podocyte injure[J]. J Am Soe Nephrol,2005,16(2):408-416.

    [19] YE H, BAI X, GAO H, et al. Urinary podocalyxin positive-element occurs in the early stage of diabetic nephropathy and is correlated with a clinical diagnosis of diabetic nephropathy[J]. J Diabetes Complications,2014,28(1):96-100.

    [20] 劉静,殷俊,陈晓岚,等.特发性膜性肾病中抗M型磷脂酶A2受体抗体、血管生成素样蛋白-4及可溶性尿激酶型纤溶酶原激活物受体的临床意义[J].南通大学学报:医学版,2017,37(3):196-202.

    [21] 庄克生,杨洪庆,李连朝,等.自拟芪藤通络饮经验方治疗特发性膜性肾病50例[J].环球中医药,2018,11(1):142-145., 百拇医药(屈云 李小会 刘争辉 郭爱华)
上一页1 2 3 4